Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for SUTENT
- OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults
- A Phase 3 Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib
- Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors
- ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST
- The Bioequivalence Study of Two Sunitinib Products in Capsules 50 mg in Healthy Volunteers Under Fasting Conditions
- Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of Imatinib
- ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling
- Pulsatile High-dose Sunitinib Versus TAS-102 in Patients With Metastatic Colorectal Carcinoma (mCRC)
- A Study of Abemaciclib in Combination With Sunitinib in Metastatic Renal Cell Carcinoma
- A Study of DCC-2618 vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib
- Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma
- Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer
- Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines (Style Trial)
- Study of Propranolol Plus Sunitinib in First-line Treatment of Metastatic Renal Cell Carcinoma
- Trial of Sunitinib Plus Nivolumab After Standard Treatment in Advanced Soft Tissue and Bone Sarcomas
- Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)
- A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
- Alternative Schedule Sunitinib in Metastatic Renal Cell Carcinoma: Cardiopulmonary Exercise Testing
- Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCC
- Study to Evaluate Efficacy and Safety of Sunitinib in Renal Cell Carcinoma Progressed to 1L Immunotherapy Treatment.
- Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma
- A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme
- A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney Cancer
- Study in Which Therapy is Either Switched to Nivolumab After 3 Months of Treatment or Therapy is Continued With a Tyrosine Kinase Inhibitor in Patients With Metastatic Renal Cell Carcinoma (RCC) and Disease Control
- Combining Sunitinib, Temozolomide and Radiation to Treat Patients Diagnosed With Glioblastoma
- The Drug Rediscovery Protocol (DRUP Trial)
- Combined Alternating Sunitinib and Bevacizumab (Avastin®) in Advanced Renal Cell Carcinoma (CASA)
- Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia
- Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed
- Efficacy of Rechallenge With Sunitinib in Metastatic Pancreatic Neuroendocrine Tumor Previously Failed to Sunitinib
- TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)
- A Prospective Study on Sunitinib as First Line Therapy for Advanced/Metastatic Renal Cell Carcinoma in Asian Population
- A Study of Sunitinib in Patients With Metastatic or Recurrent Thymic Carcinoma
- Personalized Targeted Inhibitors Treatment in Renal Cell Cancer
- A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
- Intratumoral Vaccination With Intuvax Pre-nephrectomy Followed by Sunitinib Post-nephrectomy vs Sunitinib Post-nephrectomy in Newly Diagnosed Metastatic Renal Cell Carcinoma (mRCC)
- A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC)
- CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors
- A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced Melanoma
- A Phase II Trila of Sunitinib Schedule 4/2 vs. Shedule 2/1 as First Line Therapy in Metastatic Renal Cell Carcinoma.
- Multiple Treatments for Ebola Virus Disease (EVD)
- Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)
- Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II
- Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable GIST
- CRIZENT: Crizotinib and Sunitinib in Metastatic Breast Cancer
- Adjuvant Sunitinib or Valproic Acid in High-Risk Patients With Uveal Melanoma
- Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC)
- A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) as Monotherapy or in Combination With Bevacizumab (Avastin®) Compared to Sunitinib (Sutent®) in Participants With Untreated Advanced Renal Cell Carcinoma
- Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer
- Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma
- Efficacy Study of Sunitinib and Everolimus (Rotational vs Sequential Arm) in Pats. With m Clear Cell Renal Cancer
- The Influence of Phenotype, Grapefruit Juice and Orange Juice on the Pharmacokinetics of Sunitinib in Cancer Patients
- Sunitinib Malate Related Fatigue in Patients With Metastatic Kidney Cancer
- A Study of Sunitinib in Patients With Advanced Cholangiocarcinoma
- Masitinib in Patients With Gastrointestinal Stromal Tumour After Progression With Imatinib
- A Subject Treatment Preference Study of Tivozanib Versus Sunitinib in Subjects With Metastatic RCC
- Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer
- Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
- A Phase II Study of Sunitinib Versus Dacarbazine in the Treatment of Patients With Metastatic Uveal Melanoma
- A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors
- Phase II Study of Alternating Sunitinib and Temsirolimus
- Study of Efficacy and Safety of Sunitinib Given on an Individualized Schedule
- Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma
- Cardiovascular and Torsades de Pointes Monitoring for Pazopanib
- Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2
- Study of Sutent®/Sunitinib (SU11248) in Subjects With NF-1 Plexiform Neurofibromas
- First International Randomized Study in Malignant Progressive Pheochromocytoma and Paraganglioma
- Sorafenib in Elderly Patients With Metastatic Renal Cell Carcinoma
- IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma
- Maximal Androgen Depletion Followed by Randomization of Maximal Androgen Ablation With Molecular Targeted Therapies
- Sunitinib Malate and Bevacizumab in Treating Patients With Kidney Cancer or Advanced Solid Malignancies
- Trial of Maintenance SUO11248 Versus Placebo Post Chemotherapy for Patients With Advanced Urothelial Carcinoma
- Predictive Biomarkers of Response to Sunitinib in the Treatment of Poorly-differentiated NEURO-Endocrine Tumors
- Study of Sunitinib in Patients With Advanced/Inoperable Fibrolamellar Carcinoma
- Sunitinib as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
- Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma
- Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
- Sunitinib Malate in Treating Patients With Previously Untreated Metastatic Kidney Cancer
- Pazopanib Versus Sunitinib in the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma
- Sunitinib Plus Temsirolimus in Patients With Renal Cell Cancer (RCC)
- Sunitinib Malate in Treating Patients With Recurrent Transitional Cell Bladder Cancer
- Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma
- Post Marketing Surveillance On The Safety And Tolerability Of Sunitinib Malate (Sutent) For Filipino Patients
- Study of Sunitinib in Subjects With High Risk Renal Cell Carcinoma
- Patient Preference Study of Pazopanib Versus Sunitinib in Advanced or Metastatic Kidney Cancer
- Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by Surgery
- Trial of Adjuvant Sutent for Patients With High Risk Urothelial Carcinoma After Neoadjuvant Chemotherapy and Cystectomy
- Sunitinib in Metastatic Renal Cancer
- Magnetic Resonance Imaging (MRI) in Predicting Response to Sunitinib Malate in Patients With Locally Advanced or Metastatic Kidney Cancer
- Sunitinib in Patients With Advanced Gastric Cancer and Treated With FOLFIRI
- Salvage Therapy With Sunitinib,Docetaxel and Platinum on Metastatic or Unresectable Non Small Cell Lung Cancer
- A Trial Of CVX-060, An Anti-Angiogenic COVX-Body, In Combination With Sunitinib In Patients With Advanced Renal Cell Carcinoma
- Sunitinib Malate in Treating Patients With Persistent or Recurrent Clear Cell Ovarian Cancer
- Study of Lenalidomide in Combination With Sunitinib to Evaluate the Safety and Efficacy in Patients With Renal Cell Carcinoma
- Maintenance Therapy With Sunitinib or Observation in Metastatic Pancreatic Cancer
- Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma
- Magnetic Resonance Imaging (MRI) in Predicting Response to Sunitinib Malate in Patients With Locally Advanced or Metastatic Kidney Cancer
- Sunitinib Malate in Refractory Germ Cell Tumors
- Sunitinib Malate After Stereotactic Radiosurgery in Treating Patients With Newly Diagnosed Brain Metastases
- Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck
- Exemestane With Sunitinib (SUTENT®) in Metastatic Breast Cancer
- Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy
- Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast Cancer
- Ixabepilone and Sunitinib Malate in Treating Patients With Progressive Advanced Solid Tumors
- Study In Patients With Kidney Cancer Treated With Sutent
- Sunitinib Non Small Cell Lung Cancer Patients Over 70
- To Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 386 When Used in Combination With AMG 706, Bevacizumab, Sorafenib, or Sunitinib.
- Sunitinib in Certain Subtypes of Soft Tissue Sarcomas
- Activity Study of Sunitinib In Metastatic Pretreated Urothelial Cancer
- Sunitinib in Treating Patients With Kidney Cancer That Has Spread to the Brain
- Sunitinib Malate and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Chemotherapy
- FOLFIRI and Sunitinib in Metastatic Colorectal Cancer
- Bacillus Calmette-Guerin Followed by Sunitinib for the Treatment of High Risk Non-muscle Invasive Lower Urinary Tract Urothelial Carcinoma
- Sunitinib as Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Transitional Cell Cancer
- A Phase Ib Study of Rad001 and Sutent to Treat Renal Cell Carcinoma
- Sunitinib Malate and Capecitabine in Treating Patients With Unresectable or Metastatic Liver Cancer
- Clinical Study of SU 11248 (Sutent) Combined With Standard Chemotherapy in Patients With FLT3 Mutated AML Over 60 Years
- Capiri-sutent Phase-1 in Advanced Colo-rectal Cancer
- Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma
- An Open-label Phase II Study With SUTENT in Patients Suffering From Hormone Refractory Prostate Cancer
- Multimodality Phase II Study in Prostate Cancer
- Sutent + Taxol for Advanced Esophageal Cancer
- Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma
- Special Investigation For Gist Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan).
- Special Investigation For Renal Cell Carcinoma (RCC) Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan)
- Pre-Surgical Sutent in Renal Cell Carcinoma (RCC)
- Study Of SU011248 In Combination With Docetaxel In Patients With Advanced Cancer
- Study of CGC-11047 When Used in Individual Combinations With 1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab or 4) Erlotinib or 5) Cisplatin or 6) 5-Flurouracil or 7) Sunitinib in Patients With Advanced Solid Tumors or Lymphoma
- Sunitinib in Treating Patients With Relapsed or Refractory Esophageal or Gastroesophageal Junction Cancer
- Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR]
- Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
- Irinotecan, Carboplatin, and Sunitinib in First Line Extensive-Stage Small Cell Lung Cancer
- Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy
- Non-Interventional Study (NIS) In Patients With Advanced And/Or Metastatic Renal Cell Carcinoma (mRCC) Treated With SUTENT®
- Study Testing the Biologic Activity and Safety of a Immunotherapeutic in Patients With Newly Diagnosed Advanced Stage Kidney Cancer in Combination With a Marketed Renal Cell Carcinoma Treatment
- Study of Sunitinib Malate in Patients With Newly Diagnosed Prostate Cancer Prior to Prostatectomy
- Study Of Sunitinib With FOLFIRI In Colorectal Cancer
- Sutent Adjunctive Treatment of Differentiated Thyroid Cancer
- Sunitinib in Patients With Renal Cells Carcinoma Metastasic or Locally Avanced in Patients Not Candidates to Curative Previous Nefrectomy
- Clinical Trial of Sutent to Treat Metastatic Melanoma
- Sunitinib Malate, Hormone Ablation and Radiation Therapy in Patients With Prostate Cancer
- Combination of Temsirolimus and Bevacizumab in Patient With Metastatic Renal Cell Carcinoma
- Sunitinib, Cyclophosphamide, and Methotrexate in Treating Patients With Metastatic Breast Cancer
- Sunitinib Maintenance Therapy After Induction Platinum-Based Chemotherapy in Patients With ES-SCLC
- A Phase II Trial of Sutent (Sunitinib; SU011248) for Recurrent Anaplastic Astrocytoma and Glioblastoma
- Study Of Sunitinib Plus FOLFOX In Patients With Solid Tumors
- Phase II Sunitinib Prog Met AIPC
- Interaction Study of Rapamycin and Sunitinib in Patients With Advanced Cancers
- Erlotinib and Sunitinib in NSCLC
- SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma
- Treatment of Advanced Renal Cell Carcinoma With Quinacrine
- Bevacizumab With or Without Sunitinib in Sunitinib-Refractory Renal Cell Carcinoma
- Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma
- Study Of Sunitinib In Combination With Cisplatin/Capecitabine Or Oxaliplatin/Capecitabine In Patients With Advanced Gastric Cancer
- Sutent Maintenance After Response to Taxotere
- Bevacizumab in Multiple Phase I Combinations
- Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell Cancer
- Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI
- SUTENT (SUNITINIB, SU11248)in Patients With Recurrent or Progressive Glioblastoma Multiforme
- Sunitinib in Treating Patients With Locally Advanced Bladder Cancer
- Sunitinib and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
- Sunitinib Malate in Treating East African Patients With Kaposi Sarcoma
- Study of Safety and Functional Imaging of cG250 and Sunitinib in Patients With Advanced Renal Cell Carcinoma
- Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer
- Sunitinib in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
- Sunitinib in Treating Patients With Relapsed Multiple Myeloma
- Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer
- Thyroid Cancer and Sunitinib
- Sunitinib in Treating Patients With Recurrent Malignant Gliomas
- Sunitinib Malate in Treating Patients With Unresectable or Metastatic Kidney Cancer or Other Advanced Solid Tumors
- Sunitinib Malate (SUO11248) In Subjects W/ Metastatic And/Or Surgically Unresectable Hepatocellular Cancers (HCC)
- A Study Evaluating the Efficacy and Safety of Sunitinib With or Without Bevacizumab in First-Line Patients With Metastatic Renal Cell Cancer (SABRE-R)
- Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma
- Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV Eye Melanoma
- A Study of Neoadjuvant Sutent for Patients With Renal Cell Carcinoma
- Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer
- Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas
- Efficacy And Safety Of Sunitinib In Women With Advanced Breast Cancer
- Sunitinib Malate in Patients With Non-Clear Cell Renal Cell Cancer
- Sutent and Radiation as Treatment for Limited Extent Metastatic Cancer
- Sunitinib and Gemcitabine in Treating Patients With Pancreatic Cancer or Other Solid Tumors
- Sunitinib in Treating Patients With Kidney Cancer That Cannot Be Removed by Surgery
- Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib Malate in Treating Patients With Extensive-Stage Small Cell Lung Cancer
- Sunitinib in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
- Post Marketing Surveillance Study To Observe Safety And Efficacy Of Sutene
- Phase 2 Study of Panzem® NCD Alone and Combined With Sunitinib Malate in Patients With Metastatic Renal Cell Carcinoma
- Phase IB Study Using Sunitinib Plus Radiation Therapy for Cancer Patients
- Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization
- A Study Of Sunitinib Compared To Placebo For Patients With Advanced Pancreatic Islet Cell Tumors
- A Clinical Trial Assessing Efficacy and Safety of Sunitinib and Exemestane in Patients With ER [Estrogen Receptor] + and/or PgR [Progesterone Receptor] + Breast Cancer
- Study of Combination of Sirolimus and Sutent in Patients With Advanced Solid Tumors Non-Curable With Standard Therapy
- Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma
- Sutent Following Chemotherapy, Radiation and Surgery For Resectable Esophageal Cancer
- Sunitinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Sunitinib in Treating Patients With Metastatic Pancreatic Cancer That Progressed After First-Line Therapy With Gemcitabine
- Trial of Maintenance SUO11248 Versus Placebo Post Chemotherapy for Patients With Advanced Urothelial Carcinoma
- Sunitinib in Treating Patients With Relapsed or Refractory Diffuse or Mediastinal Large B-Cell Lymphoma
- Sunitinib in Treating Patients With Advanced Malignant Pleural Mesothelioma
- Sunitinib Malate in Treating Patients With Uterine Cervical Cancer That is Stage IVB, Recurrent, or Cannot Be Removed By Surgery
- Sunitinib Malate in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
- Sunitinib in Treating Young Patients With Refractory Solid Tumors
- Sunitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
- Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery
- Sunitinib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
- Study Tests The Safety And Effectiveness Of SU011248 In Patients With Non-Small Cell Lung Cancer Having Brain Metastases
- Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors
- Study Of SU011248 In Combination With Docetaxel And Trastuzumab In Patients With Advanced Breast Cancer HER-2 Positive
- SU011248 in Combination With Irinotecan and Cetuximab as a Second Line Regimen for Stage IV Colorectal Cancer
- Bevacizumab and Sunitinib in Treating Patients With Solid Tumors
- Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have VHL Lesions to Follow
- Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
- Temodar and Sutent as Therapy for Melanoma
- Study of SU11248 in Men With Advanced Prostate Cancer
- Study Of SU011248 In Combination With Docetaxel In Patients With Metastatic Breast Cancer
- A Study In Patients With Non-Small Cell Lung Cancer Testing If Erlotinib Plus SU011248 (Sunitinib) Is Better Than Erlotinib Alone
- Study Of SU011248 Versus Chemotherapy For Patients With Previously Treated Triple Receptor Negative Breast Cancer
- Study Of SU011248 In Combination With Docetaxel (Taxotere) And Prednisone In Patients With Prostate Cancer
- Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma
- A Treatment Protocol for Patients With Gastrointestinal Stromal Tumor (GIST) Who May Derive Benefit From Treatment With SU011248
Clinical trials list
click for details